Zacks Investment Research upgraded shares of AEGERION PHARMA (AEGR) from UNDERPERFORM to NEUTRAL on February 27, 2014, with a target price of $62.50.
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on AEGERION PHARMA (AEGR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment